PTC Therapeutics Gains Sephience Approvals and Reports Positive PIVOT-HD, $1.94B Cash
PTC Therapeutics secured Sephience approvals in the US, Europe and Japan within six months and initiated a global launch with broad uptake. The company ended the year with over $1.94 billion in cash and reported positive Phase II PIVOT-HD results while advancing its early-stage pipeline toward cash-flow breakeven.
1. Strong Execution at JPM Healthcare Conference
At the 44th Annual J.P. Morgan Healthcare Conference, PTC Therapeutics CEO Matt Klein reported full delivery on the company’s 2025 objectives. PTC secured first approvals for its novel PKU therapy, Sephience, in the U.S., Europe, Japan and several other markets within six months. The global launch of Sephience has seen broad uptake across both pediatric and adult patient segments. PTC ended the year with outstanding revenue growth, disciplined expense management and a cash balance of over 1.94 billion, positioning the company on a clear path toward cash flow breakeven. Early‐stage programs also advanced, most notably the positive Phase II readout for votoplam in Huntington’s disease.
2. Significant Insider Selling by Executives
In early January, multiple PTC executives, including the CFO and CEO, sold portions of their holdings. The CFO sold 2,139 shares, reducing his stake by 2.3%, while the CEO disposed of 3,016 shares, trimming his holding by 0.75%. These transactions were disclosed in SEC filings and reflect broader insider sales by directors and senior leaders. Although profit-taking is common following strong operational results, the concentrated nature of these sales will be closely watched by investors for any impact on near-term sentiment.